INNOVENT BIO (01801) recently reached a commercialization agreement in mainland China with Eli Lilly and Co (LLY.US) for the latter's non-covalent (reversible) BTK inhibitor "Jaypalin."
According to the Zhitong Finance APP, Bank of America Securities released a research report stating that INNOVENT BIO (01801) recently reached a commercialization agreement in mainland China with Eli Lilly and Co (LLY.US) for the latter's non-covalent (reversible) BTK inhibitor "Jaypalin." After incorporating the sales forecast for this product, the firm's revenue forecasts for 2025 and 2026 have been raised by 1.9% and 3.4% respectively, and the Target Price has been adjusted from HKD 54.1 to HKD 56.4, reaffirming the "Buy" rating.
The report stated that HANSOH PHARMA (03692) earlier entered into an agreement with Merck to grant exclusive global licensing for the development, production, and commercialization of the preclinical oral small molecule GLP-1 receptor agonist HS-10535. Bank of America has raised its revenue and earnings per share forecasts for 2025 by 6.9% and 19.2%, respectively, with the Target Price adjusted from HKD 23.9 to HKD 24, reaffirming the "Buy" rating.
